Yiming Biotech's anti-LILRB4 antibody IO-202 received FDA Fast Track designation

On February 17, Immune-Onc Therapeutics announced that the investigational anti-LILRB4 antibody IO-202 has been granted Fast Track designation by the US FDA for the treatment of relapsed or refractory acute myeloid leukemia (AML)

Myeloid cell immune checkpoint inhibitors are expected to overcome the limitations of existing immunotherapy, and have become an important frontier in the development of new tumor immunotherapy drugs

Previously, Yiming Bio and the University of Texas published original research in the journal Nature, elucidating the role of LILRB4 in immunosuppression and tumor infiltration in acute myeloid leukemia (AML), and in 2021 U.

According to the press release of Yiming Bio, IO-202 is an inhibitory antibody targeting LILRB4, which has broad potential in the immunotherapy of hematological and solid tumors

▲The mechanism of action of IO-202 (Image source: Provided by Yiming Biology)

IO-202 is currently in Phase 1 clinical development for the indications of acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML)

In addition to IO-202, Yiming Bio's R&D pipeline also includes a variety of myeloid immune checkpoint inhibitor drugs

references:

[1] IO-202, the world’s first-targeted LILRB4 myeloid immune checkpoint inhibitor, was granted FDA Fast Track designation for the treatment of relapsed or refractory acute myeloid leukemia.

(Original abridged)